5Albertsen BK, Schruder H, Ingerslev J,et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol, 2001, 115:983-990. 被引量：1
6Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Eseherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children' s Cancer Group study. Blood,2002, 99 : 1986-1994. 被引量：1
7Koerholz D, Brueck M, Nuemberger W, et al. Chemical and immunological characteristics of four different L-asparaginase preparations. Eur J Haematol, 1989,42:417-424. 被引量：1
8Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res, 2004, 10:5335-5341. 被引量：1
9Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev, 2003, 55:1293-1302. 被引量：1
10Mauz-Korholz C, Junker R, Gobel U, et al. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli L-asparaginase. Thromb Haemost,2000, 83:840- 843. 被引量：1
